Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265476 | 1.00 | GAA (0.39) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL2266329 | 0.82 | GAA (0.40) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL2224728 | 0.79 | HDAC1 (0.38) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL2224718 | 0.79 | HDAC1 (0.38) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL2357273 | 0.76 | HDAC4 (0.36) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL14243980 | 0.76 | TSHR (0.47) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL12517104 | 0.76 | TSHR (0.47) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL2223339 | 0.76 | HDAC8 (0.43) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL12518546 | 0.72 | HDAC8 (0.40) | GAATSHRKMT2ALMNAHDAC8 | |
| SCHEMBL2267431 | 0.72 | HDAC8 (0.40) | GAATSHRKMT2ALMNAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| EP-2523560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | GAA 1423/4885TSHR 1177/4885KMT2A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.